Response Genetics Inc. signed an exclusive commercial agreement with the Knight Diagnostic Laboratories at Oregon Health & Science University, OHSU, for a proprietary next generation sequencing panel for lung cancer. The panel provides full gene sequencing of the actionable genes for lung cancer rather than detection only of so-called hot spots. The collaboration will leverage Response Genetics's national sales force and the company expects to begin marketing the proprietary panel immediately.

With the addition of the OHSU next-generation sequencing panel for lung cancer, Response Genetics now offers oncologists and patients analyses of actionable genetic markers across six different tumor types and four different testing modalities.